CoChat

Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Brief Review

Open access
Myers, G. · 2018 · Current Oncology
Cited by 116

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Immune checkpoint inhibitors (ICIS) such as inhibitors of CTLA-4, PD-1, and PD-L1, given as monotherapy or combination therapy have emerged as effective treatment options for immune-sensitive solid tumours and hematologic malignancies. The benefits of icis can be offset by immune-related adverse events (irAES) that leave all organ systems vulnerable and subsequently increase the risk for morbidity and mortality. Because of fluctuating onset and prolonged duration, the toxicities associated with iraes represent a shift from the understanding of conventional anticancer toxicities. The CTLA-4 and PD-1/PD-L1 inhibitors odulate T-cell response differently, resulting in distinct toxicity patterns, toxicity kinetics, and dose–toxicity relationships. Using individualized patient education, screening, and assessment for the early identification of iraes is key to proactive management and is therefore key to improving outcomes and prolonging therapy. Management of irAES is guided by appropriate grading, which sets the stage for the treatment setting (outpatient vs. inpatient), ICI treatment course (delay vs. discontinuation), supportive care, corticosteroid use, organ specialist consultation, and additional immunosuppression. Health care professionals in oncology must work collaboratively with emergency and community colleagues to facilitate an understanding of irAES in an effort to optimize seamless care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3747/co.25.4235

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 116

Metadata

Authors
Myers, G.
Venue
Current Oncology
Publisher
MDPI AG
Published
2018-10-01
Volume
25
Issue
5
Pages
342-347
ISSN
  • 1198-0052 (ISSN-L)
  • 1718-7729
OpenAlex
W2898845456
Cited by
116
References
9
FWCI
5.98
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Brief Review. https://app.cochat.ai/papers/10.3747/co.25.4235
The paper
Myers, G. (2018). Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Brief Review. Current Oncology. https://doi.org/10.3747/co.25.4235

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.